bis[(pivaloyloxy)methyl] chlorophosphate | 700865-63-0

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 有机磷酸及其衍生物
• 英文名称: bis[(pivaloyloxy)methyl] chlorophosphate
• 英文别名: bis(POM) chloro phosphate；bis(POM)chloro phosphate；bis(POM)phosphoryl chloride；((Chlorophosphoryl)bis(oxy))bis(methylene) bis(2,2-dimethylpropanoate)；[chloro(2,2-dimethylpropanoyloxymethoxy)phosphoryl]oxymethyl 2,2-dimethylpropanoate
• CAS: 700865-63-0
• 化学式: C₁₂H₂₂ClO₇P
• 分子量: 344.729
• InChiKey: MRXWWKVTUSFHQI-UHFFFAOYSA-N

物化性质

• 沸点：
  394.1±27.0 °C(Predicted)
• 密度：
  1.222±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  21
• 可旋转键数：
  10
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.83
• 拓扑面积：
  88.1
• 氢给体数：
  0
• 氢受体数：
  7

反应信息

• 作为反应物：
  描述：

  bis[(pivaloyloxy)methyl] chlorophosphate 在 2,6-二甲基吡啶 、 potassium dihydrogenphosphate 作用下， 以 二氯甲烷 为溶剂， 反应 30.0h， 生成
  参考文献：
  名称：

  Enzymatic and cellular study of a serotonin N-acetyltransferase phosphopantetheine-based prodrug

  摘要：

  Serotonin N-acetyltransferase (arylalkylamine N-acetyltransferase, AANAT) regulates the daily rhythm in the production of melatonin and is therefore an attractive target for pharmacologic modulation of the synthesis of this hormone. Previously prepared bisubstrate analogs show potent inhibition of AANAT but have unfavorable pharmacokinetic properties due to the presence of phosphate groups which prevents transfer across the plasma membrane. Here, we examine a bis-pivaloyloxymethylene (POM)-tryptamine-phosphopantetheine prodrug (2) and its biotransformations in vitro by homogenates and pineal cells. Compound 2 is an efficient porcine liver esterase substrate for POM cleavage in vitro although cyclization of the phosphate moiety is a potential side product. Tryptamine phosphopantetheine (3) is converted to tryptamine-coenzyme A (CoA) bisubstrate analog (1) by human phosphoribosyl pyrophosphate amidotransferase (PPAT) and dephosphocoenzyme A kinase (DPCK) in vitro. Compound 2 was found to inhibit melatonin production in rat pineal cell culture. It was also found that the POM groups are readily removed to generate 3; however, further processing to tryptamine-CoA (1) is much slower in pineal extracts or cell culture. Implications for CoA prodrug development based on the strategy used here are discussed. (c) 2006 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2006.12.016
• 作为产物：
  描述：

  hydrogen bis(POM)phosphate 在 草酰氯 、 N,N-二甲基甲酰胺 作用下， 以 二氯甲烷 为溶剂， 反应 2.0h， 生成 bis[(pivaloyloxy)methyl] chlorophosphate
  参考文献：
  名称：

  A phosphorylated prodrug for the inhibition of Pin1

  摘要：

  Fmoc-pSer-psi[(Z)CH = C]-Pro-(2)-N-(3)-ethylaminoindole 1, showed moderate inhibition towards the mitotic regulator, Pin1 (IC50 = 28.3 mu M). To improve the cell permeability, the charged phosphate was masked as the bis-pivaloyloxymethyl (POM) phosphate in Fmoc-(bisPOM)-pSer-psi[(Z)CH = C]-Pro-(2)-N-(3)-ethylaminoindole 2. Antiproliferative activity towards A2780 ovarian cancer cells of 1 (IC50 = 46.2 mu M) was improved significantly in 2 (IC50 = 26.9 mu M), comparable to the IC50 of 1 towards Pin1 enzymatic activity. (c) 2007 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2007.09.073

文献信息

• CYCLOPENTENYL PURINE DERIVATIVE OR SALT THEREOF
  申请人：Fujifilm Corporation

  公开号：US20210155644A1

  公开（公告）日：2021-05-27

  An object of the present invention is to provide a compound exhibiting an excellent drug efficacy as an anti-adenoviral agent, and an anti-adenoviral agent. The present invention provides an anti-adenoviral agent including a compound represented by General Formula [1] (in the formula, R 1 represents a hydrogen atom, a halogen atom, an amino group which may be substituted, a monocyclic nitrogen-containing heterocyclic ring group which may be substituted (provided that a nitrogen atom forming the ring is bonded to a carbon atom to which R 1 is bonded), a monocyclic nitrogen- and oxygen-containing heterocyclic ring group which may be substituted (provided that a nitrogen atom forming the ring is bonded to a carbon atom to which R 1 is bonded), a C 1-6 alkoxy group which may be substituted, a hydroxyl group which may be protected, or the like; R 2 represents a hydrogen atom or an amino protecting group; R 3 represents a C 1-20 alkoxy group which may be substituted, an aryloxy group which may be substituted, an amino group which may be substituted, or the like; R 4 represents a C 1-20 alkoxy group which may be substituted, an aryloxy group which may be substituted, an amino group which may be substituted, or the like; and X represents an oxygen atom or a sulfur atom) or a salt thereof.

  本发明的一个目的是提供一种作为抗腺病毒药剂具有优异药效的化合物，以及一种抗腺病毒药剂。本发明提供了一种包括由通式[1]表示的化合物的抗腺病毒药剂 （在公式中，R 1 表示氢原子、卤素原子、可能被取代的氨基、可能被取代的单环氮含杂环基团（前提是形成环的氮原子与R 1 结合的碳原子相结合）、可能被取代的单环氮和氧含杂环基团（前提是形成环的氮原子与R 1 结合的碳原子相结合）、可能被取代的C 1-6 烷氧基、可能被保护的羟基等；R 2 表示氢原子或氨基保护基团；R 3 表示可能被取代的C 1-20 烷氧基、可能被取代的芳氧基、可能被取代的氨基等；R 4 表示可能被取代的C 1-20 烷氧基、可能被取代的芳氧基、可能被取代的氨基等；X表示氧原子或硫原子）或其盐。
• CYCLOBUTYL PURINE DERIVATIVE OR SALT THEREOF
  申请人：FUJIFILM Corporation

  公开号：US20210147456A1

  公开（公告）日：2021-05-20

  An object of the present invention is to provide a compound exhibiting an excellent drug efficacy as an anti-adenoviral agent, and an anti-adenoviral agent. The present invention provides a compound represented by General Formula [1] (in the formula, R 1 represents a halogen atom, an amino group which may be substituted, a C 1-6 alkoxy group which may be substituted, a hydroxyl group which may be protected, or the like; R 2 represents a hydrogen atom or an amino protecting group; R 3 represents a C 1-20 alkoxy group which may be substituted, an aryloxy group which may be substituted, an amino group which may be substituted, or the like; R 4 represents a C 1-20 alkoxy group which may be substituted, an aryloxy group which may be substituted, an amino group which may be substituted, or the like); or a salt thereof.

  本发明的一个目的是提供一种作为抗腺病毒药剂的化合物，以及一种抗腺病毒药剂。本发明提供一种由通式[1]表示的化合物 （在该式中，R 1 代表卤原子，可能被取代的氨基，可能被取代的C 1-6 烷氧基，可能被保护的羟基等；R 2 代表氢原子或氨基保护基；R 3 代表可能被取代的C 1-20 烷氧基，可能被取代的芳氧基，可能被取代的氨基等；R 4 代表可能被取代的C 1-20 烷氧基，可能被取代的芳氧基，可能被取代的氨基等）；或其盐。
• [EN] PHOSPHOPANTETHEINE COMPOUNDS ALONE OR IN COMBINATION WITH HMG-COA REDUCTASE INHIBITORS FOR LOWERING SERUM CHOLESTEROL AND SERUM TRIGLICERIDES<br/>[FR] COMPOSÉS DE PHOSPHOPANTÉTHÉINE SEULS OU EN COMBINAISON AVEC DES INHIBITEURS DE HMG-COA RÉDUCTASE PERMETTANT D'ABAISSER LE CHOLESTÉROL SÉRIQUE ET LES TRIGLYCÉRIDES SÉRIQUES
  申请人：ACIES BIO D O O

  公开号：WO2016102680A1

  公开（公告）日：2016-06-30

  The invention relates to the use of phosphopantetheine compounds alone and in combination with 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors. Preferred medical uses relate to the treatment or prevention of dyslipidemia.

  这项发明涉及单独使用及与3-羟基-3-甲基戊二酸辅酶A还原酶抑制剂联合使用磷脂酰泛醌化合物。优选的医疗用途涉及治疗或预防血脂异常。
• [EN] ORGANOPHOSPHATE DERIVATIVES<br/>[FR] DÉRIVÉS D'ORGANOPHOSPHATE
  申请人：JANUARY THERAPEUTICS INC

  公开号：WO2019027905A1

  公开（公告）日：2019-02-07

  Provided herein are organophosphates and pharmaceutical compositions comprising said compounds.

  本文提供了有机磷化合物和包含该类化合物的药物组合物。
• [EN] STABLE PANTETHEINE DERIVATIVES FOR THE TREATMENT OF PANTOTHENATE KINASE ASSOCIATED NEURODEGENERATION (PKAN) AND METHODS FOR THE SYNTHESIS OF SUCH COMPOUNDS<br/>[FR] DÉRIVÉS DE PANTÉTHÉINE STABLES POUR LE TRAITEMENT DE LA NEURODÉGÉNÉRESCENCE ASSOCIÉE À LA PANTOTHÉNATE KINASE (PKAN) ET PROCÉDÉS DE SYNTHÈSE DE CES COMPOSÉS
  申请人：ACIES BIO D O O

  公开号：WO2015063177A1

  公开（公告）日：2015-05-07

  The invention relates to (S)-acyl-4'-phosphopantetheine derivatives, methods of their synthesis, and related medical uses of such compounds. Preferred medical uses relate to the treatment of neurodegenerative diseases, such as PKAN.

  该发明涉及（S）-酰基-4'-磷酰泛酰胺衍生物，其合成方法以及这些化合物的相关医学用途。首选的医学用途与治疗神经退行性疾病有关，例如PKAN。